Viking Therapeutics, Inc. (VKTX)

Michael Scally MD

Doctor of Medicine
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics

VKTX : Summary for Viking Therapeutics, Inc. - Yahoo Finance

[Basically, a LGND spin-off. IMO, ultimate failure. But a possible trade for profit. Be Careful.

Our lead clinical program is VK5211, a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery.

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
 

rugerjitsu

Member
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics

VKTX : Summary for Viking Therapeutics, Inc. - Yahoo Finance

[Basically, a LGND spin-off. IMO, ultimate failure. But a possible trade for profit. Be Careful.

Our lead clinical program is VK5211, a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery.

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

Buy now, and sell after earnings bump this week??
 

Michael Scally MD

Doctor of Medicine

Riding the shirt tail of MDGL. Profit but be careful. Their drug will not be approved. Nor, can they afford the trials so maybe hope for a buyout [doubtful].

Caveat Emptor ...

Viking Therapeutics: Sell The Pop On The Sympathy Play
Viking Therapeutics: Sell The Pop On The Sympathy Play - Viking Therapeutics (NASDAQ:VKTX) | Seeking Alpha

· VKTX rose as a sympathy play to MDGL as investors surmise that the good data on MGL-3196 increases the probability of success for VK2089.

· VKTX has had substantial dilution of more than 100% over the last year at much lower prices to today which I think will be a significant overhang.

· Most perilously, VKTX has an open at-the-market common share purchase agreement with Lincoln Park Capital Fund, a fund known for dilutive financing deals.

· I expect VKTX's stock to decline in the coming days to a price marginally above where it was prior to Thursday.
 
VKTX has developed a sarm or peptide that is improving NASH and fatty liver. If it passes trials it will be worth a fortune. I am keeping up to date on this new drug.
 
Top